Morgan Stanley’s Zymeworks ZYME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $62.1M | Sell |
2,480,568
-112,512
| -4% | -$2.66M | ﹤0.01% | 1875 |
|
|
2025
Q4 | $68.3M | Sell |
2,593,080
-1,391,505
| -35% | -$30.4M | ﹤0.01% | 1784 |
|
|
2025
Q3 | $68.1M | Sell |
3,984,585
-193,029
| -5% | -$2.76M | ﹤0.01% | 1742 |
|
|
2025
Q2 | $52.4M | Buy |
4,177,614
+104,151
| +3% | +$1.24M | ﹤0.01% | 1883 |
|
|
2025
Q1 | $48.5M | Sell |
4,073,463
-127,974
| -3% | -$1.75M | ﹤0.01% | 1847 |
|
|
2024
Q4 | $61.5M | Sell |
4,201,437
-905,432
| -18% | -$12.7M | ﹤0.01% | 1645 |
|
|
2024
Q3 | $64.1M | Buy |
5,106,869
+867,422
| +20% | +$9.45M | ﹤0.01% | 1605 |
|
|
2024
Q2 | $36.1M | Sell |
4,239,447
-871,697
| -17% | -$7.76M | ﹤0.01% | 2050 |
|
|
2024
Q1 | $53.8M | Sell |
5,111,144
-4,611,428
| -47% | -$51.2M | ﹤0.01% | 1692 |
|
|
2023
Q4 | $101M | Buy |
9,722,572
+5,237,854
| +117% | +$41.7M | ﹤0.01% | 1715 |
|
|
2023
Q3 | $28.4M | Sell |
4,484,718
-1,001,080
| -18% | -$7.39M | ﹤0.01% | 2092 |
|
|
2023
Q2 | $47.4M | Sell |
5,485,798
-77,503
| -1% | -$694K | ﹤0.01% | 1618 |
|
|
2023
Q1 | $50.3M | Sell |
5,563,301
-10,079
| -0.2% | -$87.9K | 0.01% | 1539 |
|
|
2022
Q4 | $43.8M | Buy |
5,573,380
+314,405
| +6% | +$2.21M | 0.01% | 1612 |
|
|
2022
Q3 | $32.3M | Buy |
5,258,975
+3,299,737
| +168% | +$19.9M | ﹤0.01% | 1694 |
|
|
2022
Q2 | $10.4M | Sell |
1,959,238
-374,790
| -16% | -$2.27M | ﹤0.01% | 3030 |
|
|
2022
Q1 | $15.3M | Buy |
2,334,028
+219,456
| +10% | +$1.96M | ﹤0.01% | 2420 |
|
|
2021
Q4 | $34.7M | Sell |
2,114,572
-181,850
| -8% | -$3.79M | ﹤0.01% | 1631 |
|
|
2021
Q3 | $66.7M | Sell |
2,296,422
-20,225
| -0.9% | -$672K | 0.01% | 1099 |
|
|
2021
Q2 | $80.4M | Buy |
2,316,647
+574,073
| +33% | +$18.2M | 0.01% | 988 |
|
|
2021
Q1 | $55M | Buy |
1,742,574
+198,929
| +13% | +$8.08M | 0.01% | 1114 |
|
|
2020
Q4 | $73M | Buy |
1,543,645
+1,149,999
| +292% | +$53.4M | 0.01% | 866 |
|
|
2020
Q3 | $18.3M | Sell |
393,646
-106,661
| -21% | -$3.66M | ﹤0.01% | 1548 |
|
|
2020
Q2 | $18M | Buy |
500,307
+298,202
| +148% | +$11M | ﹤0.01% | 1489 |
|
|
2020
Q1 | $7.17M | Buy |
202,105
+39,334
| +24% | +$1.61M | ﹤0.01% | 2093 |
|
|
2019
Q4 | $7.4M | Sell |
162,771
-32,347
| -17% | -$1.18M | ﹤0.01% | 2762 |
|
|
2019
Q3 | $4.84M | Buy |
195,118
+98,441
| +102% | +$2.47M | ﹤0.01% | 2911 |
|
|
2019
Q2 | $2.13M | Buy |
96,677
+74,085
| +328% | +$1.36M | ﹤0.01% | 3727 |
|
|
2019
Q1 | $366K | Sell |
22,592
-31,467
| -58% | -$488K | ﹤0.01% | 4734 |
|
|
2018
Q4 | $794K | Buy |
54,059
+46,579
| +623% | +$611K | ﹤0.01% | 4452 |
|
|
2018
Q3 | $117K | Buy |
7,480
+3,880
| +108% | +$55.5K | ﹤0.01% | 5640 |
|
|
2018
Q2 | $53K | Buy |
+3,600
| New | +$55.8K | ﹤0.01% | 5904 |
|
|
2017
Q4 | – | Sell |
-300
| Closed | -$2K | – | 6667 |
|
|
2017
Q3 | $2K | Hold |
300
| – | – | ﹤0.01% | 6410 |
|
|
2017
Q2 | $3K | Buy |
+300
| New | +$3.36K | ﹤0.01% | 6423 |
|
Other funds holding ZYME
EC
RCMNY
BI
PA
VCM
NI
Morgan Stanley's ZYME Position: Q1 2026 in Review
Morgan Stanley reduced its Zymeworks (ZYME) stake by 4.3% in Q1 2026, selling an estimated $2.66M and leaving 2,480,568 shares worth $62.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1875.
Morgan Stanley first reported a position in ZYME in Q2 2017 and has held it in 34 quarters since. The position peaked at $101M in Q4 2023. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.
- Morgan Stanley held 2,480,568 shares of Zymeworks worth $62.1M as of Q1 2026.
- Morgan Stanley sold 112,512 Zymeworks shares in Q1 2026, an estimated $2.66M.
- Zymeworks made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #1875 holding.
- Morgan Stanley first reported a position in Zymeworks in Q2 2017 and has held it in 34 quarters since.
- Morgan Stanley's Zymeworks position peaked at $101M in Q4 2023.
- 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.